Lais Bastos Nogueira
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Lais Bastos Nogueira has a total of 47 co-authors. Here are the top co-authors by number of shared publications:
Alexsandro S. Galdino
Laboratório de Biotecnologia de Microrganismos, Universidade Federal de São João Del-Rei, Divinópolis, MG, 35501-296, Brazil
4 shared publicationsJuliana M. Machado
Laboratório de Biotecnologia de Microrganismos, Universidade Federal de São João Del-Rei, Divinópolis, MG, 35501-296, Brazil
3 shared publicationsMariana Campos-Da-Paz
Laboratório de Nanobiotecnologia, Universidade Federal de São João Del-Rei, Divinópolis, MG, 35501-296, Brazil
3 shared publications- Carina Nogueira Garcia
Digital Biomarkers for Oncology Group, German Cancer Research Center (DKFZ), Heidelberg, Germany
2 shared publications - Ciro Martins Gomes
Universidade de Brasília, Brasil
2 shared publications Daniel S. Dias
Laboratório de Biotecnologia de Microrganismos, Universidade Federal de São João Del-Rei, Divinópolis, MG, 35501-296, Brazil
2 shared publications
Latest Publications
- Open Access
- 1 September 2021
- Published by Elsevier in Anais Brasileiros de Dermatologia (Versão em Português)
- Vol. 96 (5) , 527-538
Micobacterioses cutâneas não-tuberculose
- 1 September 2021
- Published by Elsevier in Anais Brasileiros de Dermatologia (Versão em Português)
- Vol. 96 (5) , 527-538
Open AccessMicobacterioses cutâneas não-tuberculose
- Open Access
- 16 July 2021
- Published by Elsevier in Anais Brasileiros de Dermatologia
- Vol. 96 (5) , 527-538
Non-tuberculous cutaneous mycobacterioses
- 16 July 2021
- Published by Elsevier in Anais Brasileiros de Dermatologia
- Vol. 96 (5) , 527-538
Open AccessNon-tuberculous cutaneous mycobacterioses
- 25 October 2019
- Published by Bentham Science Publishers Ltd. in Recent Patents on Biotechnology
- Vol. 13 (4) , 316-328
A Custom-Designed Recombinant Multiepitope Protein for Human Cytomegalovirus Diagnosis
The Human Cytomegalovirus (HCMV) has infected more than 90% of the world population and its prevalence can be related to the individuals geographical and socialeconomic status. Serological tests based on ELISA are pivotal for HCMV diagnosis. Due to the lack of standardization in the production/purification of antigens from viral preparations, ELISA tests are based on several recombinant proteins or peptides. As an alternative, multiepitope proteins may be employed. In this work, we developed a recombinant multiepitope protein (rMEHCMV) for HCMV diagnosis based on conserved and immunodominant epitopes derived from tegument (pp150, pp65 and pp28), glycoprotein gB (pp38) and DNA polymerase subunit (pp52) of HCMV. The rMEHCMV gene was synthesized de novo and overexpressed in Escherichia coli cells. The recombinant protein was purified to homogeneity using a Ni-NTA column. Biophysical analysis of recombinant protein was performed by circular dichroism. A preliminary biological activity test was performed using 12 positive human sera samples by using an in-house IgG ELISA. The following patents database were consulted: Espacenet, Google Patents and the National Institute of Intellectual Property (INPI, Brazil). The recombinant multiepitope protein was successfully expressed in E. coli. The structural data obtained by circular dichroism spectroscopy showed that rMEHCMV is structurally disordered. An in-house IgG ELISA test with rMEHCMV was successfully used to recognized IgG from human serum samples. Together, our results show that rMEHCMV should be considered as a potential antigenic target for HCMV diagnosis.
- 25 October 2019
- Published by Bentham Science Publishers Ltd. in Recent Patents on Biotechnology
- Vol. 13 (4) , 316-328
A Custom-Designed Recombinant Multiepitope Protein for Human Cytomegalovirus Diagnosis
The Human Cytomegalovirus (HCMV) has infected more than 90% of the world population and its prevalence can be related to the individuals geographical and socialeconomic status. Serological tests based on ELISA are pivotal for HCMV diagnosis. Due to the lack of standardization in the production/purification of antigens from viral preparations, ELISA tests are based on several recombinant proteins or peptides. As an alternative, multiepitope proteins may be employed. In this work, we developed a recombinant multiepitope protein (rMEHCMV) for HCMV diagnosis based on conserved and immunodominant epitopes derived from tegument (pp150, pp65 and pp28), glycoprotein gB (pp38) and DNA polymerase subunit (pp52) of HCMV. The rMEHCMV gene was synthesized de novo and overexpressed in Escherichia coli cells. The recombinant protein was purified to homogeneity using a Ni-NTA column. Biophysical analysis of recombinant protein was performed by circular dichroism. A preliminary biological activity test was performed using 12 positive human sera samples by using an in-house IgG ELISA. The following patents database were consulted: Espacenet, Google Patents and the National Institute of Intellectual Property (INPI, Brazil). The recombinant multiepitope protein was successfully expressed in E. coli. The structural data obtained by circular dichroism spectroscopy showed that rMEHCMV is structurally disordered. An in-house IgG ELISA test with rMEHCMV was successfully used to recognized IgG from human serum samples. Together, our results show that rMEHCMV should be considered as a potential antigenic target for HCMV diagnosis.
- 1 October 2019
- Published by Elsevier in Research in Veterinary Science
- Vol. 126, 4-8
Diagnostic markers selected by immunoproteomics and phage display applied for the serodiagnosis of canine leishmaniosis
- 1 October 2019
- Published by Elsevier in Research in Veterinary Science
- Vol. 126, 4-8
Diagnostic markers selected by immunoproteomics and phage display applied for the serodiagnosis of canine leishmaniosis
- Open Access
- 18 September 2019
- Published by Bentham Science Publishers Ltd. in Recent Advances in Food, Nutrition & Agriculture
- Vol. 10 (2) , 131-139
Expression and Biochemical Characterization of a Yersinia intermedia Phytase Expressed in Escherichia coli
Background: Phytases are enzymes capable of degrading phytic acid and used in animal feed supplementation in order to improve digestibility through the release of minerals such as phosphorus. Objective: The main goal of this study was to express and characterize a Yersinia intermedia phytase expressed in Escherichia coli cells. Methods: The Y. intermedia phytase gene was synthesized and overexpressed in Escherichia coli cells. The phytase recombinante (rPHY) was purified to homogeneity using a Ni-NTA column. The biochemical and biophysical properties of the rPHY were measured in order to fully characterize the recombinant enzyme. The following patents database were consulted: Espacenet, USPTO, LATIPAT, Patent Scope, WIPO and Google Patents. Results: The results showed that the rPHY is active at 37-40ºC and presented an optimal pH and temperature of 8.0 and 40°C, respectively. The phytase rPHY was activated by Cu2+ ion and showed resistance to trypsin and pepsin, retaining 55% of the activity at the ratio of 0.02. Furthermore, the dissociation constant (Kd = 1.1150 ± 0.0087 mM), as estimated by a fluorescence binding assay, suggests a medium affinity of the enzyme with the substrate. Conclusion: The results of this article can be considered as innovative and for this reason, they were protected by Intellectual Property Law in Brazil. Take together, the biochemical properties of the rPHY could be useful in future for its industrial application of this enzyme as an additive in the monogastric feed.
- 18 September 2019
- Published by Bentham Science Publishers Ltd. in Recent Advances in Food, Nutrition & Agriculture
- Vol. 10 (2) , 131-139
Open AccessExpression and Biochemical Characterization of a Yersinia intermedia Phytase Expressed in Escherichia coli
Background: Phytases are enzymes capable of degrading phytic acid and used in animal feed supplementation in order to improve digestibility through the release of minerals such as phosphorus. Objective: The main goal of this study was to express and characterize a Yersinia intermedia phytase expressed in Escherichia coli cells. Methods: The Y. intermedia phytase gene was synthesized and overexpressed in Escherichia coli cells. The phytase recombinante (rPHY) was purified to homogeneity using a Ni-NTA column. The biochemical and biophysical properties of the rPHY were measured in order to fully characterize the recombinant enzyme. The following patents database were consulted: Espacenet, USPTO, LATIPAT, Patent Scope, WIPO and Google Patents. Results: The results showed that the rPHY is active at 37-40ºC and presented an optimal pH and temperature of 8.0 and 40°C, respectively. The phytase rPHY was activated by Cu2+ ion and showed resistance to trypsin and pepsin, retaining 55% of the activity at the ratio of 0.02. Furthermore, the dissociation constant (Kd = 1.1150 ± 0.0087 mM), as estimated by a fluorescence binding assay, suggests a medium affinity of the enzyme with the substrate. Conclusion: The results of this article can be considered as innovative and for this reason, they were protected by Intellectual Property Law in Brazil. Take together, the biochemical properties of the rPHY could be useful in future for its industrial application of this enzyme as an additive in the monogastric feed.
- 6 August 2019
- Published by Bentham Science Publishers Ltd. in Recent Patents on Biotechnology
- Vol. 13 (3) , 170-186
Recent Patents Applications in Red Biotechnology: A Mini-Review
Background: The different fields of biotechnology can be classified by colors, as a "rainbow" methodology. In this sense, the red biotechnology, focused on the preservation of health, has been outstanding in helping to solve this challenge through the provision of technologies, including diagnostic kits, molecular diagnostics, vaccines, innovations in cancer research, therapeutic antibodies and stem cells. Objective: The main goal of this work is to highlight the different areas within the red Biotechnology. In this sense, we revised some patents regarding red biotechnology as examples to cover this subject. Methods: A literature search of patents was performed from the followings Patents Database: INPI, USPTO, Esp@cenet, WIPO and Google Patents. Results: Our analysis showed the following numbers from patents found: cancer research (8), diagnosis kit (9), vaccines (8), stem cells (9) and therapeutic antibodies (5), where the United States is the leader for most filled patents in Red Biotechnology. Conclusion: This mini-review has provided an update of some patents on Recent Patents in Red Biotechnology. As far as we know, this is the first mini-review report on Red Biotechnology based on patents.
- 6 August 2019
- Published by Bentham Science Publishers Ltd. in Recent Patents on Biotechnology
- Vol. 13 (3) , 170-186
Recent Patents Applications in Red Biotechnology: A Mini-Review
Background: The different fields of biotechnology can be classified by colors, as a "rainbow" methodology. In this sense, the red biotechnology, focused on the preservation of health, has been outstanding in helping to solve this challenge through the provision of technologies, including diagnostic kits, molecular diagnostics, vaccines, innovations in cancer research, therapeutic antibodies and stem cells. Objective: The main goal of this work is to highlight the different areas within the red Biotechnology. In this sense, we revised some patents regarding red biotechnology as examples to cover this subject. Methods: A literature search of patents was performed from the followings Patents Database: INPI, USPTO, Esp@cenet, WIPO and Google Patents. Results: Our analysis showed the following numbers from patents found: cancer research (8), diagnosis kit (9), vaccines (8), stem cells (9) and therapeutic antibodies (5), where the United States is the leader for most filled patents in Red Biotechnology. Conclusion: This mini-review has provided an update of some patents on Recent Patents in Red Biotechnology. As far as we know, this is the first mini-review report on Red Biotechnology based on patents.